Rituximab for delayed hemolytic transfusion reactions in adults with SCD: a case series of 10 patients in Kinshasa, Democratic Republic of Congo
Journal of Sickle Cell Disease · 15.01.2026 · 3 (1)
DOI: 10.1093/jscdis/yoag043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Sickle Cell Disease, online erschienen am 14.10.2026. Verfasst von Serge Kabamba Mwamba und 9 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To describe the clinical, biological, and immunohematological characteristics of delayed hemolytic transfusion reactions (DHTR) in adults with SCD and their outcomes following multimodal management including rituximab as rescue therapy in a resource-limited setting.
Methods
We retrospectively reviewed 10 adults with homozygous SS SCD who developed DHTR after red blood cell transfusion at Monkole Hospital Centre, Kinshasa, between January 2023 and December 2025. Diagnosis was based on clinical, transfusional, and biological findings, after excluding alternative causes of acute hemolysis.
Results
Patients were predominantly female, with a median age of 26 years. DHTR occurred a median of 7 days post-transfusion. All patients developed severe acute anemia (median Hb nadir, 4.0 g/dL) with elevated hemolysis markers. Direct antiglobulin tests (DAT) and red blood cell alloantibody screenings (indirect antiglobulin test) were negative in most cases; anti-Kell antibody was detected in 1 patient. All patients received short-course corticosteroids and erythropoietin, followed by rituximab (fixed dose, 500 mg) as part of multimodal rescue management. Clinical and biological improvement was observed from day 3 after rituximab initiation. Seven patients required intensive care, and 1 died from ACS.
Conclusion
DHTR is a severe, often under-recognized complication in adults with SCD in sub-Saharan Africa. This case series highlights diagnostic challenges and describes favorable clinical and biological evolution following multimodal rescue therapy including rituximab, underscoring the need for prospective studies.
Zitieren
APA
Mwamba, S. K., Ndaie, G. M., Kasongo, M., Baliejukia, B. B., Kukila, J., Ngasia, B., Kitenge, R., Matanda, D. T., Mbuyi, F. M., & Diasonama, J. K. (2026). Rituximab for delayed hemolytic transfusion reactions in adults with SCD: a case series of 10 patients in Kinshasa, Democratic Republic of Congo. Journal of Sickle Cell Disease, 3(1). https://doi.org/10.1093/jscdis/yoag043
Vancouver
Mwamba SK, Ndaie GM, Kasongo M, Baliejukia BB, Kukila J, Ngasia B, et al. Rituximab for delayed hemolytic transfusion reactions in adults with SCD: a case series of 10 patients in Kinshasa, Democratic Republic of Congo. Journal of Sickle Cell Disease. 2026;3(1). doi:10.1093/jscdis/yoag043
BibTeX
@article{Mwamba2026,
author = {Mwamba, Serge Kabamba and Ndaie, Gorby Mpoyi and Kasongo, Michael and Baliejukia, Boaz Baliesima and Kukila, Jonathan and Ngasia, Baron and Kitenge, Robert and Matanda, Denis Tshitemb and Mbuyi, Freddy Mukishi and Diasonama, Jean-François Konde},
title = {Rituximab for delayed hemolytic transfusion reactions in adults with SCD: a case series of 10 patients in Kinshasa, Democratic Republic of Congo},
journal = {Journal of Sickle Cell Disease},
year = {2026},
volume = {3},
number = {1},
doi = {10.1093/jscdis/yoag043}
}
EUVIMED